Alexander Gray and Mike Rea from IDEA Pharma explain why the current pharma R&D model is broken, and how it’s hindering commercialisation for companies across the industry
In this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing recent changes in China, England and the US and asking how pharma can work with he
We are in the most competitive period ever for the pharmaceutical industry, characterised by incremental innovation and looming patent cliffs – and path-to-market strategy firm IDEA Pharma
Brexit will allow UK pharma to rid itself of the bureaucracy of Europe’s drug regulation system and a culture that is failing to nurture innovation, according to one independent thinker.
As the ASCO congress drew to a close, Johnson & Johnson filed for FDA approval of its BCMA-targeting CAR-T therapy Carvykti for use earlier in the treatment pathway fo
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas